MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

2019 International Congress

September 22-26, 2019. Nice, France.

View by Title View Sessions
View by Date
Jump to:  View All • a b c d e f g h i j k l m n o [p] q r s t u v w x y z
  • Pain assessment and pain management study in patients with Parkinson’s disease in Uzbekistan

    A. Umarov, D. Tolibov (Tashkent, Uzbekistan)

  • Pain in patients with multiple system atrophy: a pain-related evoked potential study

    M. Takeda, F. Okada, H. Tachibana, S. Kasama, H. Yoshikawa (Nishinomiya, Japan)

  • Pallidal surgery and physiological mechanism in choreic movements

    T. Hashimoto, T. Goto, K. Yoshida, L. Johnson, J. Vitek (Minneapolis, MN, USA)

  • Pantothenate kinase-associated neurodegeneration in Tunisian families

    H. Benrhouma, I. Kraoua, H. Klaa, A. Rouissi, EM. Valente, I. Benyoussef Turki (Tunis, Tunisia)

  • Parakinesia brachialis oscitans due to an acute medial cerebral artery stroke

    V. Gadelha, F. Germiniani, M. Lange, F. Nascimento, F. Zorzetto, P. Dos Santos, H. Teive (Curitiba, Brazil)

  • Paraneoplastic Cerebellar Degeneration As Initial Symptom Of Renal Cell Carcinoma

    S. Souza, B. Oliveira, I. Sodré, A L. Oliveira, R. Oliveira, D. Terrana, M. Spitz (Rio de Janeiro, Brazil)

  • Paresthesia and gait impairment in a patient with advanced Parkinson disease-case report

    IE. Petre, M. Marian (Bucharest, Romania)

  • Park-Ease Trial: A Randomized Controlled Trial to Study the Efficacy of Exercises in Early-Stage Parkinson’s Disease

    R. Swarnakar, S. Wadhwa, S. V, V. Goyal, V. Sreenivas (New Delhi, India)

  • Parkinson Disease Clinical Subtypes Predict Dementia and Mortality Risk

    P. Myers, M. Campbell, A. Weigand, N. Cairns, J. Jackson, C. Lessov-Schlaggar, J. Perlmutter (St. Louis, MO, USA)

  • PARKINSON DISEASE HAMPERS PARTICIPATION IN THE CIVIC RESPONSIBILITY OF VOTING: a study of barriers to expression of a fundamental human right

    O. Oguntunde, O. Ojo, O. Agabi, M. Rizig, N. Okubadejo (Lagos, Nigeria)

  • Parkinson Kinetigraph – does it change the management of PD patients?

    F. Bergquist, A. Cvejtkovic, AC. Sjöström, S. Wallerstedt (Gothenburg, Sweden)

  • Parkinson´s Disease, respiratory capacity and functionality: a Physical Therapy perspective

    V. Israel, B. Yamaguchi, A. Silva, D. Iucksch, J. Siega (Curitiba, Brazil)

  • Parkinson’s Disease Correlates with Reduced Risk of Hypertension

    S. Khakimova, KH. Daminova (Tashkent, Uzbekistan)

  • Parkinson’s disease patients with both GBA and LRRK2 mutations are phenotypically similar to LRRK2 – a possible protective effect?

    N. Omer, A. Thaler, L. Goldstein, A. Orr-Urtreger, M. Gana Weisz, O. Goldstein, D. Cohen Avinoam, M. Kestenbaum, M. Lioti, S. John, J. Cederbaum, A. Mirelman, N. Giladi (Tel Aviv, Israel)

  • Parkinson’s Disease Presentation in Calabar, Nigeria

    S. Oparah, U. Williams, J. Mwankon (Calabar, Nigeria)

  • Parkinson’s disease-associated mutations of PLA2G6 alters the membrane dynamics and α-synuclein stability

    a. Mori, T. Hatano, T. Inoshita, K. Shiba-Fukushima, T. Koinuma, C. Yamashita, A. Okuzumi, Y. Imai, n. Hattori (Tokyo, Japan)

  • Parkinson’s disease and intermittent hypoxia training: beneficial or harmful?

    M. Sharifi-Bonab, J. Sesink, B. Bloem, D. Devos, J. Deguil, C. Moreau (Nijmegen, Netherlands)

  • Parkinson’s disease and melanoma: a serie of 33 patients

    J. Doridam, M. Nader, A. Melin, MF. Avril, E. Maubec, B. Degos (Paris, France)

  • Parkinson’s disease in Middle East, North Africa and South Asia: Consensus from the MDS Task Force on the Middle East

    H. Khalil, L. Chahine, J. Junaid Siddiqui, M. Salari, S. El-Jaafary, Z. Aldaajani, M. Abu Al-Melh, T. Mohammad, M. Abu Snineh, N. Syed, M. Bhatt, M. Habib, M. Habahbeh, S. Tabbal, B. Jeon, J. Bajwa (Irbid, Jordan)

  • Parkinson’s disease Polygenic Risk Factor Scores in Patients with Inflammatory Bowel Disease

    H. Maghzi, D. Li, E. Hogg, A. Garland-Becerra, E. Tan, A. Maghzi, D. Mcgovern, M. Tagliati (Los Angeles, CA, USA)

  • Parkinson’s disease polygenic risk score is not associated with impulse control disorders: a longitudinal study

    J. Ihle, F. Artaud, S. Bekadar, G. Magnone, H. Bertrand, S. Sambin, LL. Mariani, C. Scherzer, A. Elbaz, JC. Cornol (Paris, France)

  • Parkinson’s Disease Treatments and Outcomes: US v Non-US Patients

    TL. Davis, M. Rafferty, K. Lyons, A. Ramirez-Zamora, H. Gao, S. Wu, F. Cubilllos, EC. Nelson (Lebanon, NH, USA)

  • Parkinson’s Panorama: Epidemiology and Non-motor Symptoms, Revisiting Taboo Topic of Sexual Dysfunction in a Malaysian Parkinson’s Population

    Y Y. Tan, K. Tan (Georgetown, Malaysia)

  • Parkinsonian syndrome associated to C9orf72 expansion

    S. Novo Ponte, E. Gamo González, P. Sánchez Alonso (Majadahonda, Spain)

  • Parkinsonism alters directed connectivity in the cortico-subthalamo-pallidal circuit

    D. Escobar Sanabria, L. Johnson, Y. Yu, J. Zhang, S. Nebeck, Z. Busby, G. Molnar, J. Vitek (Minneapolis, MN, USA)

  • Parkinsonism and other motor features in familial frontotemporal dementia with mutations in the MAPT, GRN, or C9orf72 gene (LEFFTDS cohort)

    A. Deutschlander, R. Savica, M. Heckman, D. Brushaber, J. Syrjanen, H. Rosen, A. Boxer, B. Boeve, Z. Wszolek (Jacksonville, FL, USA)

  • Parkinsonism and rapidly progressive dementia secondary to free-living ameba

    M. Rubio Hernandez, I. Rodriguez Leyva, M. Tello Zavala, A. Ortiz Alvarez, C. Gallegos Rios (San Luis Potosi, Mexico)

  • Parkinsonism in a movement disorder reference center in El Salvador

    D. Pereira (San Salvador, El Salvador)

  • Parkinsonism in HIV positive persons in South Africa

    FH. Amod (Durban, South Africa)

  • PARKMIM: A Transversal Pilot Study on Hemihypomimia in Parkinson Disease

    M. Kurtis, C. Gasca, T. Maycas-Cepeda, P. Gomez-Sanchez, L. Lopez-Manzanares, M. Mata Alvarez-Santullano, C. Prieto-Jurcczynska, M. Eimil, L. Vela, A. Jimenez-Huete (Madrid, Spain)

  • Parotitis as Adverse Event Following BoNT Injections for Sialorrhea

    K. Papesh, J. Nguyen (Las Vegas, NV, USA)

  • Paroxysmal asymmetric dystonic arm posturing – a less recognised but characteristic manifestation of ATP1A3-related disease

    B. Balint, C. Stephen, V. Udani, C. Sankhla, N. Barad, A. Lang, K. Bhatia (Boston, MA, USA)

  • Path to Prevention (P2P) – Developing a Prodromal PD Progression Biomarker Program

    K. Marek, A. Siderowf, C. Coffey, T. Foroud, V. Arnedo, E. Flagg, S. Chowdhury, K. Kieburtz, L. Chahine, J. Seibyl (New Haven, CT, USA)

  • Pathological role of GBA2 in GBA1-related disorder

    E. Nakanishi, N. Uemura, H. Akiyama, M. Kinoshita, H. Yamakado, S. Takeda, Y. Hirabayashi, R. Takahashi (Kyoto, Japan)

  • Patient and physician perspectives on the care and assistance needs in Huntington’s disease

    K. Raimundo, R. Tan, T. To, J. de Courcy, U. Ondhia, H. Rickards, M. Nance (South San Francisco, CA, USA)

  • Patient insights into the burden of OFF-episodes in Parkinson’s disease: Qualitative Interviews

    C. Ervin, J. Sutphin, A. Thach, A. Lee, C. Mansfield, J. Coulter (Research Triangle Park, NC, USA)

  • Patient organisation collaboration to advance patient engagement in Parkinson’s research

    N. Ratcliffe, K. Schroeder (New York, NY, USA)

  • Patient-centered approach to elicit and compare the treatment goals of patients with tardive dyskinesia, their care partners, and healthcare providers

    C. Kutz (Colorado Springs, CO, USA)

  • Patient-Centered Decision Making Tool for Deep Brain Stimulation in Parkinson’s Disease and Outcome and Satisfaction Assessment

    K. Yen, J. Miyasaki, F. Ba (Edmonton, AB, Canada)

  • Patient-Centered Outcomes of Deep Brain Stimulation in Parkinson’s Disease

    R. Moraes, J. Freitas, R. Ferreira, P. Pereira, P. Terzian, F. Godinho, M. Rocha (Sao Paulo, Brazil)

  • Patients Experiencing Motor Fluctuations With Parkinson’s Disease (PD): Participant Characteristics in the Accordance Phase 3 Efficacy and Safety Trial of Accordion Pill™ Carbidopa/Levodopa

    P. Lewitt, R. Gendreau, J. Meckler, A. Hotovely-Salomon, N. Navon (West Bloomfield, MI, USA)

  • Pattern and Presentation of Parkinson Disease in two Teaching Hospitals in Enugu, South East Nigeria

    B. Ezeala-Adikaibe (Enugu, Nigeria)

  • Patterns of brain activity linked to Mild Behavioral Impairment in Parkinson’s disease

    EJ. Yoon, Z. Ismail, M. Kibreab, T. Hammer, J. Cheetham, I. Kathol, M. Ramezani, S. Lang, J. Sarna, D. Martino, S. Furtado, O. Monchi (Calgary, AB, Canada)

  • Patterns of cortical thickness, surface area and subcortical volume in Parkinson’s disease patients with freezing of gait

    T. Mi, S. Garg, A. Liu, P. Chan, M. Mckeown (Beijing, China)

  • Patterns of Lewy body dementia diagnosis and treatment in Florida

    M. Armstrong, R. Eisinger, C. Garvan, B. Patel (Gainesville, FL, USA)

  • Patterns of neuropsychological profiles according to severity of depressive symptoms in newly diagnosed Parkinson’s disease patients

    SJ. Kim (Busan, Republic of Korea)

  • Peculiarities of the indicators of MR-diffusion in children’s cerebral palsy with symptomatic epilepsy

    K. Aminov (Tashkent, Uzbekistan)

  • Pediatric anti-N-methyl-D-aspartate receptor encephalitis associated with Coat’s-like retinal telangiectasia

    N. Kumar, D. Radhakrishnana, R. Shree, G. Madhaw, R. Samanta, S. Kumari (Rishikesh, India)

  • Pediatric Deep Brain Stimulation in Secondary Dystonia using Stereotactic Depth Electrode Targeting

    M. Liker, T. Sanger (Los Angeles, CA, USA)

  • People with Parkinson’s Disease (PPD): disease, stigma and the others

    M. Bacigalupe (La Plata, Argentina)

  • Per-oral image guided gastrojejunostomy insertion for levodopa-carbidopa intestinal gel in Parkinson’s disease is safe and may be advantageous

    F. Baig, L. Mooney, M. Selikhova, M. Rolinski, K. Szewczyk-Krolikowski, N. Collin, A. Whone (Bristol, United Kingdom)

  • Peripheral Blood Mononuclear Cells (PBMCs) are Useful Biomarkers of Mitochondrial Dysfunction in Parkinson Disease Patients with Pathogenic Parkin and LRRK2 Mutations

    P. Campbell, J. Harvey, A. Costantini, H. Morris, A. Schapira (London, United Kingdom)

  • Periventricular hyperintensities and axial symptom of Parkinson’s disease

    J. Ko, Y. Lee, MK. Sunwoo, JH. Yoon, SY. Kang, JY. Hong (Wonju, Republic of Korea)

  • Permanent chorea in 76-years-old female with poorly controlled diabetes

    F. Abu Ahmad, A. Socher, A. Gadoth, O. Aizenstein, A. Hilel, R. Hurvitz-Alon, N. Giladi, T. Gurevich (Tel Aviv, Israel)

  • PEX 16: EXPANDING THE CLINICAL SPECTRUM OF PEROXISOMAL BIOGENESIS DISORDERS

    D. N, J. Agadi (Bangalore, India)

  • Pharmacokinetics of ABBV-951 Following 24-Hour Continuous Subcutaneous Infusion to Arm, Abdomen and Thigh

    M. Rosebraugh, P. Kym, W. Liu, M. Facheris, J. Benesh (North Chicago, IL, USA)

  • Pharmacokinetics of Accordion Pill™ Carbidopa/Levodopa Following Multiple Doses in Patients With Parkinson’s Disease

    C. Olanow, F. Stocchi, M. Leinonen, N. Navon, J. Meckler, R. Gendreau (Sarasota, FL, USA)

  • Pharmacokinetics of Opicapone and Effect on COMT and Levodopa Pharmacokinetics in Patients with Parkinson’s Disease

    G. Loewen, P. Lewitt, C. Olanow, K. Kieburtz, G. Liang, R. Jimenez, K. Olson, E. Roberts (San Diego, CA, USA)

  • Pharmacological effect of adenosine A2A receptor antagonist for levodopa-induced dyskinesia associated with cellular energy homeostasis

    NAO. Kanzato (Okinawa, Japan)

  • Phenotypic segregation in kindred with a novel ANO3 variant

    V. Carvalho, F. Correia, J. Martins, J. Massano, T. Temudo (Matosinhos, Portugal)

  • Phenotypic spectrum of Progressive Supranuclear Palsy in a Tunisian cohort

    A. Nasri, A. Neji, I. Kacem, T. Lansari, S. Mrabet, A. Gargouri, M. Ben Djebara, R. Gouider (Tunis, Tunisia)

  • Phenotypic variability and extreme age of presentation of GCH1 gene mutation in dopa-responsive dystonia

    F. Abu Ahmad, P. Ponger, M. Rotstein, A. Migirov Sandrovitz, N. Giladi, A. Orr-Urtreger, T. Gurevich, S. Ben-Shachar (Tel Aviv, Israel)

  • Phosphodiesterase 10A and cognition in Parkinson’s disease

    Z. Chappell, G. Pagano, H. Wilson, F. Niccolini, R. Gunn, E. Rabiner, T. Foltynie, M. Politis (London, United Kingdom)

  • Phosphodiesterase inhibitors as a treatment for Friedreich’s ataxia

    J. González-Fernández, E. Zucchet, P. Calap-Quintana, P. González Cabo, MD. Moltó Ruiz (València, Spain)

  • Physiotherapy in cervical dystonia with focus on clinical assessments on ICF

    M. Steinboeck, H. Unger (Bad Aibling, Germany)

  • Pilot Study Comparing Home Sleep Profiler to In-laboratory Polysomnogram for REM Sleep Behavior Disorder Diagnosis

    D. Shprecher, D. Levendowski, C. Guevarra, J. Lee-Iannotti, G. Lazarz (Sun City, AZ, USA)

  • Pilot testing of the Integrated Parkinson’s Disease Care Network: feasibility, efficacy outcomes and cost description analysis

    T. Mestre, D. Kessler, J. Shen, A. Basndwah, H. Shinawi, C. Nussey, A. Ohman, S. Kumar, D. Côté, C. Liddy, K. Thavorn, M. Taljaard, D. Grimes (Ottawa, ON, Canada)

  • Pisa syndrome in Parkinson’s disease: a study on the neuropsychological profile.

    E. Montanaro, CA. Artusi, S. Tuttobene, A. Romagnolo, M. Zibetti, L. Lopiano (Torino, Italy)

  • Plasma membrane Ca2+ Atpase 1 as a candidate to mediate the degeneration of dopaminergic neurons by inflammation in Parkinson’s disease

    B. Erhardt, MS. Marcora, A. Delella Ezcurra, J. Casabona, R. Tarelli, L. Frenkel, P. Bochicchio, D. Bodin, B. Silva, V. Cavaliere Candedo, MI. Farías, C. Ferrari, M. Allo, C. Höcht, A. Chernomoretz, E. Castaño, MC. Leal, F. Pitossi (Capital Federal, Argentina)

  • Plasma Soluble ST2 (sST2) levels are Higher in Neurodegeneration and Associate with PD Cognition

    ASL. Ng, YJ. Tan, ACW. Yong, BYX. Wong, ZH. Lu, SYE. Ng, SKS. Ting, S. Hameed, L. Zeng, N. Kandiah, WL. Au, LCS. Tan (Singapore, Singapore)

  • Plasma-based circulating long non-coding RNA AS-Uch1 as a novel diagnostic biomarker for Parkinson’s disease

    Y. Fan, Z. Xue (Wuhan, China)

  • PNKP deficiency mimicking a benign hereditary chorea: the misleading presentation of a neurodegenerative disorder

    C. Caputi, M. Tolve, S. Galosi, M. Inghilleri, C. Carducci, A. Angeloni, V. Leuzzi (Roma, Italy)

  • POLR3A-related spastic ataxia: new mutations and a look into the clinical and MRI phenotype

    J. Infante, KM. Serrano, E. Marco-de Lucas, A. Sánchez-Rodríguez, J. Berciano, M. Corral, X. Farré, A. Matilla (Santander, Spain)

  • Polyneuropathy in patients with continuous levodopa/carbidopa intestinal gel (LCIG) infusion

    KAM. Pauls, J. Toppila, M. Koivu, J. Eerola-Rautio, M. Udd, E. Pekkonen (Helsinki, Finland)

  • Polysomnographic features of Spinocerebellar Ataxia type 3 – a case report

    DRC. Carneiro, IL. Luzeiro, ASM. Morgadinho (Coimbra, Portugal)

  • Ponto-cortical aberrations:Neural correlations for Hypomimia in PD

    P. Singru, V. Vadiyala, E. Ganesh, V. Vinodhanand (Georgetown, Guyana)

  • Population Exposure-Response Modeling of the Effects of Apomorphine Sublingual Film on QTc in Patients With Parkinson’s Disease and “OFF” Episodes

    F. Agbo, Y. Chiu, S. Chapel, G. Galluppi, D. Blum, B. Navia (Fort Lee, NJ, USA)

  • Population Exposure-Response Models of Apomorphine Sublingual Film in Healthy Subjects and Patients With Parkinson’s Disease and “OFF” Episodes

    F. Agbo, Y. Chiu, S. Chapel, G. Galluppi, D. Blum, B. Navia (Fort Lee, NJ, USA)

  • Population Pharmacokinetics and Pharmacodynamics of Ampreloxetine (TD-9855) in Patients with Neurogenic Orthostatic Hypotension (nOH)

    A. Lo, J. Kanodia, R. Vickery, D. Bourdet (South San Francisco, CA, USA)

  • Positive response to Botulinum Toxin injections in a patient with Painless Hand with Moving Fingers: A Case Report and Literature Review

    Z. Rosensweet, A. Persaud, E. Gaitour, N. Shneyder (Jacksonville, FL, USA)

  • Post stroke dystonia and dystonic tremor: Clinical features and neuroimaging findings

    S. Pandey, P. Tater (New Delhi, India)

  • Post-pump chorea and progressive supranuclear palsy like syndrome following major cardiac surgery: A case series

    GW. Kim, KW. Park, NR. Choi, HS. Ryu, HJ. Kim, CS. Lee, SJ. Chung (Daegu, Republic of Korea)

  • Post-stroke movement disorders: an analysis of 24 cases

    M. Burzhunova, N. Garabova, L. Geraskina (Moscow, Russian Federation)

  • Posterior cortical atrophy (PCA) attributable to corticobasal degeneration

    H. Sienkiewicz-Jarosz, E. Bucior (Warsaw, Poland)

  • Postural Abnormalities in Parkinson’s Disease: an Epidemiological and Clinical Multicenter Study

    C. Geroin, M. Gandolfi, R. Ceravolo, M. Capecci, E. Andrenelli, M. Ceravolo, L. Bonanni, M. Onofrj, M. Vitale, M. Catalan, P. Polverino, C. Bertolotti, S. Mazzucchi, S. Giannoni, N. Smania, S. Tamburin, L. Vacca, F. Stocchi, F. Radicati, C. Artusi, M. Zibetti, L. Lopiano, A. Fasano, M. Tinazzi (Verona, Italy)

  • Postural alterations in patients with Progressive Supranuclear Palsy

    C. Palmisano, M. Todisco, V. Maltese, R. Cilia, N. Pozzi, A. Canessa, M. Canesi, J. Volkmann, C. Frigo, G. Pezzoli, I. Isaias (Würzburg, Germany)

  • Postural and kinetic tremor is associated with pallidal dopamine denervation in patients with Parkinson’s disease

    N. Choi, KW. Park, SH. Hong, CS. Lee (Seoul, Republic of Korea)

  • Postural Instability Assessed by Static and Dynamic Posturography in the Early Stage of Parkinson’s Disease

    A. Hajas, TW. Stone, E. Dinya, J. Málly (Sopron, Hungary)

  • Postural instability secondary to hypoxic injury to the bilateral globus pallidi

    D. Shpiner, J. Margolesky, H. Moore (Miami, FL, USA)

  • Potential involvement of the caudate nucleus in GBA-associated Parkinson’s disease

    MC. Ruppert, A. Greuel, M. Tahmasian, F. Maier, T. van Eimeren, K. Lohmann, L. Timmermann, M. Tittgemeyer, A. Drzezga, C. Eggers (Marburg, Germany)

  • Potential treatment considerations for refractory REM behavior disorder

    J. Nguyen, K. Papesh (Las Vegas, NV, USA)

  • PPN-GAB-PARK: Short time outcome and long term follow up in PPN-DBS

    C. Giordana, M. Borg, JP. Flambart, J. Bredin, D. Fontaine (Nice, France)

  • Practice Patterns with Onabotulinum Toxin-A for Movement disorders: South Asian Neurologist Survey

    G. Kumar, P. Wadia, H. Kumar, P. K, S. Gupta, V. Goyal, A. Raza, A. Zuzek, A. Patel (Bengaluru, India)

  • Pramipexole regulates the depressive-like symptom through dopamine D3 not dopamine D2 receptor in a mouse model of Parkinson’s disease

    SZ. Wei, F. Wang, CF. Liu (Suzhou, China)

  • Praxis deficits in patients with Parkinson’s disease: A neuropsychological study

    E. Rounis, G. Pizzamiglio (Oxford, United Kingdom)

  • Pre-diagnosis physical activity habits are associated with age of diagnosis and postural instability in Parkinson’s disease

    M. Landers, K. Johnson, S. Johnson, J. Lyle, T. Ormsby, D. Salgo, J. Zorn, A. Murtishaw, A. Salazar, J. Kinney (Las Vegas, NV, USA)

  • Pre-Dopa DBS: is early deep brain stimulation able to modify the natural course of Parkinson’s disease?

    M. Porta, D. Servello, AR. Bona, E. Zekaj, G. Gonzalez-Escamilla, G. Groppa (Milan, Italy)

  • Pre-frontal activation during walking in Parkinson’s disease: the impact of attention

    S. Stuart, A. Giritharan, J. Quinn, M. Mancini (Portland, OR, USA)

  • Pre-status and status dystonicus in children and adolescents

    G. Garone, F. Graziola, F. Nicita, F. Frascarelli, F. Randi, M. Zazza, L. Cantonetti, F. Vigevano, CE. Marras, A. Capuano (Rome, Italy)

  • PRECISE-PD: From pathophysiology to precision medicine for Parkinson’s disease

    JC. Corvol, S. Durrleman, S. Lehericy, D. Devos, W. Meissner, E. Bezard, D. Grosset, H. Morris, O. Monchy, EA. Fon, F. Durif, F. Tubach, Y. de Rycke, O. Rascol (Paris, France)

  • Preclinical Development of a Novel Carbidopa/Levodopa Precision Olfactory Delivery (POD®) Drug-Device Combination Product for the Treatment of OFF Episodes in Parkinson’s Disease

    K. Satterly, G. Davies, B. Gajera, J. Wright, H. Lin, S. Muppaneni, K. To, S. Shrewsbury, J. Hoekman (Seattle, WA, USA)

  • Preclinical efficacy of drugs identified by IBM-Watson for repurposing to treat L-DOPA-induced dyskinesia

    N. Visanji, A. Lacoste, P. Ravenscroft, S. Spangler, S. Fox, A. Lang, J. Brotchie, T. Johnston (Toronto, ON, Canada)

  • Preclinical profile of dopamine D1PAM: A novel mechanism in clinical development for Lewy Body dementia

    K. Svensson, J. Beck, J. Hao, J. Schaus, X. Wang, B. Heinz, S. Mitchell, K. Wafford, C. Yang, L. Zhang, S. Castner, G. Williams, H. Marston, R. Bruns (Indianapolis, IN, USA)

  • Predicting active electrode selection from atlas based targets and probabilistic sweetspots in STN DBS

    T. Dembek, P. Reker, J. Petry-Schmelzer, V. Visser-Vandewalle, M. Barbe (Cologne, Germany)

  • Predicting domain specific cognitive impairment in Parkinson’s disease

    P. Zarifkar, J. Kim, C. La, P. Borghammer, K. Poston (Palo Alto, CA, USA)

  • Predicting DRS-2 Total scores from the MoCA

    M. Zorn, K. Duff, J. Rolston, J. Ballard, C. Aquino, P. Moretti (Salt Lake City, UT, USA)

  • Predicting Impulse Control Disorders in Parkinson’s Disease: A Challenging Task

    J. Faouzi, S. Bekadar, O. Colliot, JC. Corvol (Paris, France)

  • Predicting the efficacy of STN-DBS in patients with different Parkinson’s disease motor subtypes by preoperative total and partial levodopa response

    GH. Lu, ZX. Yin, YW. Jin (Nanchang, China)

  • Predicting the functional impact on the performance of daily activities in people with PD: a novel approach based on objective measures obtained by inertial sensors

    K. Lebel, C. Duval, E. Goubault, S. Bogard, P. Blanchet (Montreal, QC, Canada)

  • Predicting the impact of Parkinson’s disease on a patient’s gait: the potential of innovative approaches based on instrumented clinical tests

    K. Lebel, C. Duval, E. Goubault, S. Bogard (Montréal, QC, Canada)

  • Predictive Factors for Depression in a Multicentric Parkinson’s Disease Mexican Cohort

    A. Banegas-Lagos, A. Cervantes-Arriaga, D. Garza-Brambila, E. Garcia-Berlanga, K. Salinas-Barboza, S. Isais-Millan, A. Anaya-Escamilla, E. Velazquez-Avila, G. Parra, A. Gonzalez-Cantú, M. Rodriguez-Violante, D. Martinez-Ramirez (Monterrey, Mexico)

  • Predictors of Health-Related Quality of Life in Patients with Cervical Dystonia

    SA. Reijneveld, Z. Gdovinova, MAJ. Tijssen, JP. van Dijk, T. Hoekstra, M. Turcanova Koprusakova, M. Smit, M. Skorvanek, V. Han (Martin, Slovakia)

  • Predictors of Orthostatic Hypotension in Patients with Parkinson’s Disease

    C-C. Lin, J. Heisler, H. Patel, W. Ondo (Houston, TX, USA)

  • Predictors of quality of life in dystonia – a longitudinal study

    J. Junker, J. Hall, B. Berman, M. Vidailhet, E. Roze, I. Malaty, J. Jankovic, S. Reich, A. Espay, N. Patel, J. Perlmutter, H. Jinnah, V. Brandt, N. Brueggemann (Luebeck, Germany)

  • Predictors of refractory impulse control disorder to dopamine agonists substitution therapy in Parkinson’s disease patients

    JY. Lee, J-H. Choi, B. Jeon, J. Cho (Seoul, Republic of Korea)

  • Predictors of Retention for Carbidopa/Levodopa Intestinal Gel in Parkinson Disease

    A. Nagy, T. Davis, T. Hassell, P. Hedera, D. Isaacs, H. Koons, F. Phibbs, S. Afrow, J. Fang (Nashville, TN, USA)

  • Preferred place of death (PPOD) in PD, PSP and MSA

    C. Morris, R. Walker, M. Lee, J. Adamson (Newcastle, United Kingdom)

  • Prefrontal cortex high beta power correlates with the severity of anxiety and depression in Parkinson’s disease patients

    C. de Hemptinne, W. Chen, C. Racine, A. Seritan, J. Mergenthaler, S. Rajagopalan, J. Ostrem, P. Starr (San Francisco, CA, USA)

  • Pregnancy and Delivery Complications in Women with Inherited Isolated Dystonia

    M. San Luciano, V. Shanker, S. Bressman, D. Raymond, R. Saunders-Pullman (San Francisco, CA, USA)

  • Preliminary validation of a novel, comprehensive digital biomarker smartphone application to assess motor symptoms in de-novo diagnosed Parkinson patients

    F. Lipsmeier, K. Taylor, E. Volkova-Volkmar, R. Postuma, T. Kilchenmann, D. Wolf, Y. Zhang, W. Cheng, A. Scotland, J. Schjodt-Eriksen, F. Boess, D. Ness, C. Gossens, A. Post, M. Lindemann (Basel, Switzerland)

  • Premature State of Oligodendrocytes Potentially Provides Critical Period for Extracellular Pathological α-Synuclein to Invade Oligodendrocyte Lineage Cells

    S. Kaji, T. Maki, T. Ayaki, R. Takahashi (Kyoto, Japan)

  • Preoperative quantitative evaluation of psychological determinants in abnormal head postures

    E. Sanrey, C. Labate, L. Cif, V. Gonzalez, E. Borgeais, E. Chan Seng, P. Coubes (Montpellier, France)

  • Preoperative Smoking History Increases Risk of Infection in Deep Brain Stimulation Surgery

    M. Sikora, F. Farrokhi, M. Marsans, S. Monsell, A. Wright, M. Palmer, A. Hoefer, P. Mcleod, J. Mark, J. Carlson (Seattle, WA, USA)

  • Preoperative stratification of gait outcome from subthalamic nucleus stimulation

    I. Cebi, M. Scholten, A. Gharabaghi, D. Weiss (Tubingen, Germany)

  • Preparing enhanced arm swing facilitates gait initiation in Parkinson’s disease: a combined EEG-EMG-IMU study

    J. Weersink, N. Maurits, B. de Jong (Groningen, Netherlands)

  • Preserved white matter microstructure in Parkinson’s disease patients with levodopa-induced dyskinesia: Evaluation by neurite orientation dispersion and density imaging (NODDI)

    T. Ogawa, T. Hatano, H. Takeshige, C. Andica, K. Kamagata, A. Saito, T. Koinuma, R. Nakamura, H. Iwamuro, G. Oyama, Y. Shimo, A. Umemura, M. Ito, S. Aoki, N. Hattori (Tokyo, Japan)

  • Prevalence and associated risk factors of early morning off among the patients with Parkinson’s disease in China

    W. Mao, C. Han, J. An, Z. Liu, P. Chan (Beijing, China)

  • Prevalence and clinical characteristics of Parkinson Disease in Chernivtsi Region of Ukraine

    O. Yaremchuk, I. Yaremchuk (Chernivtsi, Ukraine)

  • Prevalence and factors related to orthostatic hypotension and orthostatic intolerance in recently-diagnosed, drug-naïve Parkinson’s disease patients

    S. Perez-Lloret, C. Quarracino, F. Capani, M. Otero-Losada (Buenos Aires, Argentina)

  • Prevalence and Patterns of Rest and Action Tremor in Drug-naïve Parkinson’s Disease

    D. Gupta, J. Boyd, S. Kuo (Burlington, VT, USA)

  • Prevalence and predisposing factors of Parkinson disease: A barangay community-based study in Quezon, Philippines

    MC. Rosales, DJ. Robles, RCN. Rodriguez, NB. Romana, JM. Rosales, G. Salazar, R. Rosales (Manila, Philippines)

  • Prevalence and risk factors for impulsive compulsive behaviors in a cohort of Parkinson’s disease patients

    S. Simoni, N. Tambasco, P. Eusebi, P. Nigro, E. Brahimi, F. Paolini Paoletti, M. Filidei, G. Cappelletti, P. Calabresi (Perugia, Italy)

  • Prevalence of advanced Parkinson’s Disease in patients treated in the hospitals of the Spanish public health care system: PARADISE Study (interim analysis)

    JC. Martínez-Castrillo, P. Martínez-Martín, A. Burgos, G. Arroyo, N. García, MR. Luquín, JM. Arbelo (Las Palmas, Spain)

  • Prevalence of advanced Parkinson’s disease in Thai patients with Parkinson’s disease using the Consensus on the Definition of Advance Parkinson’s disease (CEPA Study): A single-center study

    J. Srikajon, P. Srivanitchapoom, Y. Pitakpatapee, A. Pisarnpong, T. Sangpeamsook, A. Suengtaworn (Bangkok, Thailand)

  • Prevalence of chronic kidney disease in patients with idiopathic Parkinson’s disease in a tertiary care hospital in Mexico City

    S. Isais-Millan, CA. Rojas-Guerrero, A. Arriaga, M. Rodriguez-Violante, D. Zuñiga-Garcia, RO. Millan-Guerrero, V. Campos-Gasga, V. Garcia-Barrera, R. Santos-Montero (Colima, Mexico)

  • Prevalence of Fabry disease among patients with Parkinson’s disease

    A. Mosejova, S. Oppermann, V. Han, P. Dosekova, J. Cobejova, M. Cobej, P. Levicka, S. Liesenerova, T. Lorincova, M. Ostrozovicova, D. Sendekova, V. Sukovska, Z. Gdovinova, P. Bauer, M. Skorvanek (Kosice, Slovakia)

  • Prevalence of Huntington’s Disease in Sardinia, Italy

    A. Muroni, MR. Murru, T. Ercoli, V. Melas, E. Casaglia, M. Melis, E. Cocco, G. Defazio (Cagliari, Italy)

  • Prevalence of Neurodegenerative movement disorders in different clinical Practices of Hyderabad, Pakistan

    M. Arain (Jamshoro, Pakistan)

  • Prevalence of Oropharyngeal Dysphagia in Hereditary Spastic Paraplegias

    L. Jacinto-Scudeiro, G. Machado, A. Ayres, D. Burguêz, M. Polese-Bonatto, C. González-Salazar, M. Siebert, M. França Jr, M. Olchik, J. SAUTE. (Porto Alegre, Brazil)

  • Prevalence of orthostatic hypotension and postprandial hypotension in neurodegenerative diseases with synucleinopathy: a systematic review and meta-analysis

    CS. Chuang, SL. Wu (Changhua, Taiwan)

  • Prevalence of Parkinson’s disease and parkinsonism in Kyrgyzstan

    C. Shambetova (Bishkek, Kyrgyzstan)

  • Prevalence of Parkinson’s disease in a district of central highlands of Peru: Preliminary report

    E. Sarapura-Castro, K. Milla-Neyra, S. Montano, I. Mata, M. Inca-Martinez, J. Rios-Pinto, C. Cosentino, P. Mazzetti, M. Cornejo-Olivas (Lima, Peru)

  • Prevalence of Parkinsonian Syndrom in the World

    MRS. Sabirova (Tashkent, Uzbekistan)

  • Prevalence of Rem Behavior Disorder (RBD) in different motor subtypes of Parkinson`s Disease corroborated by Polisomnography

    O. Cardenas, A. Abundes, M. Rodríguez, A. Cervantes, V. Alatriste (Mexico City, Mexico)

  • Prevalence of Restless Leg Syndrome in the general population of Montevideo, Uruguay in 2018

    I. Amorin, H. Hackembruch, A. Lescano, M. Aguerre, O. Echevarria, S. Faliveni, J. García, E. Monllor (Montevideo, Uruguay)

  • Primary disruption of the subsystems of the default mode network in drug-naïve Parkinson’s disease with mild cognitive impairments: a resting-state functional connectivity MRI study

    YB. Hou, QQ. Wei, RW. Ou, J. Yang, W. Song, QY. Gong, HF. Shang (Chengdu, China)

  • PRKN Positive Parkinson’s Disease Masked as Dopa-Responsive Dystonia

    S. Chiu, A. Elkouzi, L. Almeida (Gainesville, FL, USA)

  • Probabilistic tractography study of the nigrostriatal pathway in Parkinson’s disease

    S. Tagliente, H. Wilson, Z. Chappell, T. Yousaf, E. de Natale, G. Pagano (London, United Kingdom)

  • Probing Error Signals of Postural Control in Fragile X Premutation carriers

    C. O'Keeffe, M. Carro Domínguez, E. O'Rourke, N. Feerick, T. Lynch, R. Reilly (Dublin, Ireland)

  • Procedural Memory Changes of Parkinson’s Disease Patients Post Participation in Boxing

    A. Ghaffar, R. Gallagher, C. Mcleod, A. Leder (Old Westbury, NY, USA)

  • Prodromal symptoms in clinically diagnosed dementia with Lewy bodies stratified by Lewy body pathology on autopsy

    K. Wyman-Chick, D. Weintraub, M. Rosenbloom, L. Erickson, P. Martin, T. Barclay, M. Barrett (Bloomington, MN, USA)

  • Professional characteristics of people with or without impulse control disorders in Parkinson’s disease from a single centre cohort study, Moscow, Russia

    N. Titova, N. Shipilova, E. Katunina (Moscow, Russian Federation)

  • Profile and progression of cognitive deficits in Progressive Supranuclear Palsy, Multiple System Atrophy and Parkinson’s Disease

    E. Fiorenzato, A. Antonini, V. Camparini, L. Weis, C. Semenza, R. Biundo (Venice, Italy)

  • Profiling of lipoproteins and associated lipids in serum samples from Idiopathic REM Sleep Behavior Disorder patients to identify biomarkers for Parkinson’s disease

    A. Laguna, A. Iranzo, M. Serradell, N. Amigó, O. Yanes, M. Vila (Barcelona, Spain)

  • Progression of dopaminergic and serotonergic dysfunction related to motor and nonmotor manifestations in apathetic and non-apathetic parkinsonian patients: a 4-year longitudinal double-tracer PET study

    S. Prange, E. Metereau, H. Klinger, E. Schmitt, E. Lhommée, A. Bichon, D. Le Bars, A. Maillet, P. Pellissier, S. Meoni, E. Broussolle, A. Castrioto, P. Krack, S. Thobois (Bron, France)

  • Progression of neuropsychiatric symptoms in Parkinson’s disease

    J. Dlay, G. Duncan, T. Khoo, C. Williams-Gray, D. Breen, R. Barker, D. Burn, R. Lawson, A. Yarnall (Newcastle Upon Tyne, United Kingdom)

  • Progressive Myoclonus Ataxia: An International Database

    S. Vd Veen, T. de Koning, D. Sival, M. Tijssen (Groningen, Netherlands)

  • Progressive Parkinsonism and Cognitive Changes: A Rare Presentation of Chronic Lymphocytic Inflammation with Pontine Perivascular Enhancement Responsive to Steroids (CLIPPERS)

    M. Khyat-Khoei, J. Randhawa, E. Furr-Stimming, R. Samudralwar, S. Chandra (Houston, TX, USA)

  • Prolonged-release Melatonin for Sleep Disorders in Parkinson’s Disease: A Randomized trial

    JH. Ahn, M. Kim, JK. Mun, J. Youn, S. Park, W. Jang, J. Park, E. Oh, JW. Cho, JS. Kim (Seoul, Republic of Korea)

  • Prospective Characterization of Genetically Confirmed X-linked Dystonia Parkinsonism Patients and their Families: A 1 year longitudinal feasibility study

    P. Acuna, J. de Guzman, N. Ganza-Bautista, J. Lagarde, C. Go, N. Sharma (Boston, MA, USA)

  • Prospective Memory in Parkinson’s Disease: the role of the motor subtypes

    A. D'Iorio, G. Maggi, C. Vitale, D. Di Meglio, L. Trojano, G. Santangelo (Caserta, Italy)

  • Prospective observational study to follow up a cohort of Parkinson’s outpatients during a 4-week rehabilitation

    E. Leblong, AL. Roy, B. Fraudet, A. Riou, E. Ceze, A. Rouxel, B. Nicolas, P. Gallien (Rennes, France)

  • Prospective study of cognition in SCA2

    T. Monte, E. Reckziegel, M. Augustin, O. Barsottini, JL. Pedroso, F. Vargas, ML. Saraiva-Pereira, V. Leotti, L. Jardim (Porto Alegre, Brazil)

  • Prospective study on impulsive-compulsive behaviours in early Parkinson’s disease

    V. Markovic, I. Stankovic, I. Petrovic, T. Stojkovic, V. Kostic (Belgrade, Serbia)

  • Protective and therapeutic activity of Cinnamaldehyde in the mouse model of Parkinson’s disease

    S. Rajput, S. Sinha (New Delhi, India)

  • Protective effect of anodal transcranial direct current stimulation on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurotoxicity in mice via modulating mitochondrial dynamics

    W. Jang, JY. Ahn (Gangneung, Republic of Korea)

  • Protective effects of β-Nicotinamide Adenine Dinucleotide against motor deficits and dopaminergic neuronal damage in a Parkinson’s disease mouse model

    C. Shan, YL. Gong, QQ. Zhuang, YF. Hou, SM. Wang, ST. Li, JM. Liu (Shanghai, China)

  • Provider Communication About Exercise in Parkinson’s Disease Before and After DBS surgery: A Retrospective Chart Review

    I. Dustin, D. Ehrlich (Bethesda, MD, USA)

  • PRRT2 mutations are associated with a wide intrafamilial ad interfamilial phenotypic variability

    M. Vizziello, R. Dilena, A. Giacobbe, E. Monfrini, G. Franco, A. Di Fonzo (Milano, Italy)

  • PSA and VIM DBS efficiency in essential tremor depends on distance to dentatorubrothalamic tract

    JN. Petry-Schmelzer, T. Dembek, P. Reker, J. Wirths, S. Hamacher, J. Steffen, H. Dafsari, M. Hövels, G. Fink, V. Visser-Vandewalle, M. Barbe (Cologne, Germany)

  • PSP-like syndrome after aortic in adults (Mokri syndrome)

    S. Tisel, J. Ahlskog, J. Matsumoto, J. Duffy, K. Josephs (Minneapolis, MN, USA)

  • Psychosis in Prodromal Parkinson’s disease

    I. Pachi, M. Maraki, M. Kosmidis, M. Yannakoulia, E. Dardiotis, G. Hadjigeorgiou, P. Sakka, G. Xiromerisiou, M. Stamelou, N. Scarmeas, L. Stefanis (Athens, Greece)

  • Public awareness and education of Parkinson’s Disease among Nepalese Population

    R. Ojha, R. Karn (Kathmandu, Nepal)

  • Pulmonary function in patients with Parkinson’s disease

    V. Israel, B. Yamaguchi, M. Ferreira, S. Valderramas (Curitiba, Brazil)

  • Pupillary response to light and tasks in early and late onset essential tremor patients

    J. Becktepe, F. Gövert, L. Kasiske, M. Yalaz, K. Witt, G. Deuschl (Kiel, Germany)

  • Pursuit of Psychosocial Intervention for Depression and Anxiety in Japanese Parkinson’s Disease patients: Two Studies of Cognitive Behavioral Therapy

    I. Shinmei, N. Nishikawa (Tokyo, Japan)

  • Puzzle resolution as cognitive test in Parkinson´s disease patients

    C. Borrue-Fernandez, D. Santos-García, J. Pagonabarraga, B. Pascual-Sedano, M. Mata, C. Study Group (Madrid, Spain)

Jump to:  View All • a b c d e f g h i j k l m n o [p] q r s t u v w x y z

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Safety and Tolerability of a Ketone Supplement in Parkinson's Disease
  • Successful external defibrillation in a patient with bilateral deep brain stimulation
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Life expectancy with and without Parkinson’s disease in the general population
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley